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Abstract
Nano-sized materials have great potential as drug carriers for nanomedicine applications. Thanks to their size, they can exploit the
cellular machinery to enter cells and be trafficked intracellularly, thus they can be used to overcome some of the cellular barriers to
drug delivery. Nano-sized drug carriers of very different properties can be prepared, and their surface can be modified by the addi-
tion of targeting moieties to recognize specific cells. However, it is still difficult to understand how the material properties affect
the subsequent interactions and outcomes at cellular level. As a consequence of this, designing targeted drugs remains a major chal-
lenge in drug delivery. Within this context, we discuss the current understanding of the initial steps in the interactions of nano-sized
materials with cells in relation to nanomedicine applications. In particular, we focus on the difficult interplay between the initial
adhesion of nano-sized materials to the cell surface, the potential recognition by cell receptors, and the subsequent mechanisms
cells use to internalize them. The factors affecting these initial events are discussed. Then, we briefly describe the different path-
ways of endocytosis in cells and illustrate with some examples the challenges in understanding how nanomaterial properties, such
as size, charge, and shape, affect the mechanisms cells use for their internalization. Technical difficulties in characterizing these
mechanisms are presented. A better understanding of the first interactions of nano-sized materials with cells will help to design
nanomedicines with improved targeting.
Introduction
Nano-sized materials are widely studied in nanomedicine for
their potential use as drug carriers, in imaging, and for
diagnostic purposes [1-3]. Because of their size, they can
interact with cells in similar ways as other nano-sized objects,
such as proteins, cholesterol particles, and virus particles. These
natural nano-sized objects are usually recognized by specific
cell receptors at the plasma membrane and they are internalized
by cells using the cell endocytic machinery [4]. Similarly,
engineered nano-sized materials can exploit the cellular ma-
chinery to be internalized by cells. In fact, since the cell mem-
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brane blocks diffusion of complexes larger than ca. 1 kDa,
nano-sized materials, such as nanomedicines, are transported
into cells using energy-dependent mechanisms, unlike many
small drugs currently present on the market [5]. This enables
nanomedicines to potentially overcome problems associated
with the passive diffusion of small molecular drugs through cell
membranes, such as their indiscriminate internalization in dif-
ferent cell types and organs, which is often associated with side
effects [6]. Additionally, nanomedicines can encapsulate differ-
ent types of hydrophilic and hydrophobic drugs, and they can be
designed to control their release profile [7]. Several other char-
acteristics of nanomaterials such as size, material, shape, sur-
face charge, hydrophobicity, roughness, and elasticity can be
tailored in order to meet various needs [3,8]. This high engin-
eering potential can be exploited to control the distribution and
behaviour of nanomedicines in biological environments. By
tuning nanomedicine design, parameters such as serum–protein
interactions, sequestration by the immune system, blood circu-
lation time, biodistribution, and cellular recognition and intern-
alization can be tailored [1-3,7,8]. Moreover, the surface of
nanomedicines can be engineered by introducing functional
groups to reduce clearance and increase biodistribution, as well
as for active targeting purposes [1,2,9,10]. In fact, nanomedi-
cines can be engineered to interact with specific cell receptors,
opening up new strategies for targeting specific cell types and
organs [9-12]. Despite this high engineering potential, active
targeting remains one of the major challenges for nanomedi-
cine success [13,14], and so far only few targeted nanomedi-
cines are currently present in the market, even if several are in
clinical trials [6].
Recent advances in the field have shown the complexity of
achieving targeted uptake by specific cells. For example, it has
been shown that the biomolecules adsorbing on the nanoparti-
cles once they are introduced in biological environments and
the resulting corona can screen the targeting moieties [15,16].
At the same time, it has emerged that the corona itself can be
recognized by receptors at the cell membrane [17,18] and that
this initial recognition can affect the mechanism that cells use
for the internalization of the nanoparticles [18]. However,
several aspects of the initial recognition of nano-sized materials
by cell receptors and of the molecular mechanisms leading to
their uptake and intracellular processing are still unclear [19-
21]. A better understanding of these processes can help to
design smarter nanomedicines and to achieve better targeting
[22].
Within this context, in this review we will summarise the cur-
rent understanding of the very first steps of the interactions of
nano-sized materials with cells, with a particular focus on the
initial recognition at the cell membrane and the following
Figure 1: Interaction of nano-sized materials at the cell surface. First,
nanoparticles adhere at the plasma membrane (A) and/or are recog-
nized by cell receptors. Recognition can be achieved via targeting
moieties, in the case of targeted nanomedicines (B) but also via the
biomolecular corona (C) [10,11,17,18]. Secondly, nano-sized objects
are internalized via various mechanisms (here illustrated by different
shapes in the cell membrane or a membrane protrusion). However, we
do not know yet how nanomaterial properties (such as size, shape,
charge, as illustrated in the figure) affect or determine the mechanism
cells use for the internalization [7,19-22].
mechanisms of internalization by cells. We discuss these
aspects in relation to the application of nano-sized materials for
nanomedicine. Challenges in characterizing these first events
will be illustrated, together with a brief description of the
known endocytic pathways in cells.
Review
1 Interactions of nano-sized materials at the
cell surface and recognition by
cell receptors
1.1 Active targeting
The first steps in nanoparticle–cell interactions are those
happening at the cell surface, including the adhesion of nano-
particles to the cell membrane and the potential interaction with
cell receptors (Figure 1). In order to control and affect these
first events, nano-sized carriers can be modified with targeting
moieties, such as peptides, proteins, or antibodies to specific-
ally recognize receptors on the cell surface to achieve active
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targeting [9-12]. These surface-functionalized nanomaterials
should be internalized preferentially by cells that overexpress
the targeted receptors. Examples of targeting moieties often
exploited in nanomedicine are transferrin and folate, which
target tumour cells overexpressing the corresponding receptors
[23,24], or hyaluronic acid, which directs nanocarriers to CD44-
overexpressing tumour cells [25], among many others. While
many new targeted nanomedicines are developed, just few of
them are currently present on the market [6]. In fact, achieving
efficient targeting in vivo remains a crucial challenge for drug
delivery and recently the debate on the success of nanomedi-
cine for delivering drugs to their target has been very active
[26-28].
Indeed, it is difficult to design nanoparticles that achieve specif-
ic targeting [7,9,29]. This is not only because a better under-
standing of the factors controlling the very first interactions of
nano-sized materials with live cells is still needed (as we
discuss here), but also because of challenges related to nanopar-
ticle design and presentation of the targeting moiety. For
instance, chemical coupling can affect the binding affinity of
the targeting ligand to its receptor [30]. Moreover, it is difficult
to control the targeting ligand density and its orientation. Both
factors are important for the recognition by cell receptors and
can affect cellular uptake [31,32]. Several reviews have summa-
rized these and other similar challenges in the surface functio-
nalization of nano-sized drug carriers to achieve targeting [33-
35]. Ideally, by better controlling the early interactions with
cells, nanomedicines should be recognized by the desired recep-
tors and be trafficked intracellularly to their target.
1.2 Corona formation
Another complication in achieving targeting is the formation of
the biomolecular corona. When a nanomedicine (or any nano-
sized material) comes in contact with a biological environment
(for example, blood, interstitial fluids, or extracellular matrices)
after administration, its surface is rapidly covered by various
biomolecules leading to the formation of a corona [36-39]. It
has been shown that, in some cases, the presence of the corona
can mask the targeting moieties grafted on the nanoparticle sur-
face, preventing recognition by cell receptors [15,16,40].
Corona formation can affect not only the targeting ability, but
also particle size, stability, and overall surface properties [36].
Recent guidelines have started to highlight the importance of
testing nanomedicines in the presence of relevant biological
media in order to take corona effects into account [41].
Several strategies have been developed to try to reduce protein
adsorption and corona formation. This can be achieved for
instance by grafting hydrophilic polymers such as polyethylene
glycol (PEG) on the surface of nanomedicines, or by introdu-
cing zwitterionic modifications to make nanomaterials almost
neutral [42-45]. These modifications reduce the amount of bio-
molecules bound on the surface of nanomedicines after admin-
istration (though it has been shown that PEGylated surfaces can
still adsorb proteins [46,47]) and usually also lead to decreased
uptake by cells.
At the same time, the corona confers a new biological identity
to nanomaterials and can affect the way nanomedicines are
recognized and processed by cells [3,7,8,20,21,36,48]. Biomol-
ecules present in the corona can, per se, have targeting capabil-
ities towards particular receptors [17,18,49-52]. For example,
apolipoprotein B and immunoglobulin G in the corona of
100 nm silica nanoparticles incubated with human serum were
found to interact with their corresponding receptors, low-densi-
ty lipoprotein receptor and Fc-gamma receptor I, respectively
[17]. Similarly, lipid nanoparticles were efficiently targeted to
the hepatocytes upon adsorption of apoE on their surface
following administration [52,53]. Thus, controlling the corona
composition can possibly provide new ways to control the
initial interactions of nano-sized materials with cells.
The corona composition depends on nanoparticle physicochem-
ical characteristics, such as size, shape, charge, hydrophobicity,
rigidity and surface characteristics [3,7,8,48,54]. By changing
these properties, the corona composition might be tuned to
contain components that bind to specific cell surface receptors
and initiate internalization [17,49,55-57]. Similarly, artificial
coronas can be formed to achieve recognition by specific recep-
tors. For instance, Tonigold and colleagues have shown that
pre-adsorbed antibodies, which could be seen as a form of pre-
formed corona, kept, at least partially, their targeting ability in
the presence of serum [40].
From a broader perspective, the effects of the corona on the
interactions of nanoparticles with cells are being more and more
recognized [41,58,59]. For example, multiple attempts have
been made in trying to predict how the presence of the corona
affects targeting of nanomedicines [60,61]. Similarly, it is
known that the corona composition changes not only with nano-
particle properties [3,7,8,48,54], but also depending on serum
origin [62,63], serum preparation [63-65], serum concentration
[18,66,67] or health status [68,69]. However, many more facets
of corona effects on nanoparticle–cell interactions still need to
be understood, and even more so if one aims to exploit the
corona for targeting.
Similarly, how receptor interactions affect the subsequent inter-
nalisation is also not known. Nano-sized materials and
nanomedicines may interact only with one type of receptor
(Figure 2A) or with multiple receptors at the same time
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Figure 2: Scheme of possible scenarios that can occur at the cell surface, resulting in nanoparticle uptake. Nanoparticles or their corona can be
recognized by one (A) or multiple types of receptors (B), and the recognition by receptors triggers nanoparticle uptake. Alternatively, the adhesion of
the nanoparticle to the cell surface may induce internalization without receptor engagement (C) or the receptor is only involved in the initial adhesion
of the nanoparticle, then uptake is triggered by different mechanisms, possibly induced by the nanoparticle itself (D).
(Figure 2B), and the recognition by cell receptors triggers
uptake. It might be that only high-affinity interactions contrib-
ute to the entry, or that internalization occurs after receptor
clustering. Alternatively, internalization may happen without
recognition by specific receptors (often referred to as unspe-
cific binding and unspecific uptake), possibly triggered by the
nano-sized object itself (Figure 2C). Another possibility is that
the recognition by cell receptors is involved only in the initial
adhesion to the cell membrane, but not in the internalization
(Figure 2D). A combination of all these different possibilities
may as well be present. In all cases, addressing these open ques-
tions relative to the first interactions at the cell surface is re-
quired to understand how to achieve a more efficient targeting
of nanomedicines.
2 Internalization
After the very first interactions at the plasma membrane, most
nano-sized materials are internalized by cells [19-22]. Many
questions are still open on how the initial interactions at the cell
membrane affect the mechanisms cells use for the subsequent
internalization. For instance, does receptor recognition trigger
internalization via the same pathway used for its physiological
ligands? Or do the receptors mediate just the initial adhesion
and is it the nano-sized material itself that triggers its own
internalization, perhaps by other ways (as also illustrated in
Figure 2D)? How are uptake efficiency and the mechanisms of
internalization modulated by the type of receptor engaged and/
or by the initial interactions at the cell membrane? These are ex-
amples of the many questions that the field needs to address in
order to control nanomedicine design to achieve the desired
outcomes at cell level.
In the following sections, we will summarize key aspects of the
main mechanisms of cellular internalization, i.e., endocytosis.
Then, examples of works trying to understand how nanomateri-
al properties affect the mechanisms of uptake by cells are
presented to illustrate the complexity of outcomes observed and
the difficulties in drawing conclusions.
2.1 Pathways of endocytosis in cells
Cells developed several mechanisms of endocytosis in order to
select and sort different cargoes to their intracellular destina-
tion [70,71]. Although these mechanisms differ strongly, they
also share a series of common features. As discussed by
Johannes and colleagues [72,73], common features required for
uptake to occur are (Figure 3):
• a specific lipid composition of the cell membrane at the
site of endocytosis (such as the presence of sphingol-
ipids or cholesterol) [70,72,74-76],
• cargo recognition at the cell membrane (receptor-medi-
ated or not) and capture (into coated vesicles or specific
carriers) [72,73],
• membrane bending, which occurs through different
mechanisms, including the insertion of hydrophobic
protein motifs in the membrane, local recruitment
of membrane-bending domains, or scaffolding
by proteins (the classic example being clathrin)
[72,73,77,78], and
• scission of the endocytic vesicle, which can be guided by
actin, dynamin and/or other proteins [79-83].
The specific details of each of these steps in the various
endocytic mechanisms are extensively discussed in different
excellent and specialized reviews [70,71], including some
focused on the mechanisms of endocytosis of nanomedicines
[19,21,22,85,86]. Here, we briefly summarize some of their key
aspects.
Beilstein J. Nanotechnol. 2020, 11, 338–353.
342
Figure 3: Common features of endocytic pathways [73]. Endocytosis requires a specific cell membrane composition at the site of uptake (A) [72,74-
76] and starts with the recognition of the cargo at the cell membrane (B). Subsequently, membrane bending takes place to form a vesicle (C)
[72,73,77,78,84]. Lastly, the vesicle is cleaved from the cell membrane via different mechanisms, which can involve various cellular components (e.g.,
actin and dynamin, here depicted as lines and circles, respectively) (D) [79,80].
One of the most studied endocytic mechanism is clathrin-medi-
ated endocytosis (CME). CME is a form of receptor-mediated
endocytosis that is used for the internalization of various bio-
molecules among which low density lipoprotein for cholesterol
uptake and transferrin for iron uptake. After binding of the
ligand to its receptor, clathrin, the main actor in CME, is
recruited at the cell membrane together with several other pro-
teins and assembles around the forming vesicle to form a
clathrin-coated pit. The GTP-binding protein dynamin is then
required for the scission of the clathrin-coated pit to form an
endocytic vesicle. Although it was thought to be non-essential
for CME [87], there are indications suggesting that actin fila-
ments are also involved in the scission [88,89] and especially in
the uptake of larger objects [90] via this pathway.
Next to CME, several clathrin-independent endocytic (CIE)
pathways have been described [71,91,92]. One of these path-
ways is macropinocytosis, which cells use to internalize larger
volumes of extracellular fluids and solutes. In macropinocyt-
osis, extracellular fluids are engulfed by membrane ruffles and
protrusions. Formation of these ruffles requires actin nucleation
and in some cells also cholesterol [93,94].
Another frequently studied clathrin-independent pathway
is the so-called caveolae-mediated endocytosis. Caveolae
are 50–80 nm sized cup-shaped invaginations of the plasma
membrane, consisting of lipid rafts enriched in cholesterol
and sphingolipids, and coated with caveolins [95-97].
Endocytosis of these invaginations can be both receptor-
dependent and -independent and requires actin and
dynamin [96,98,99]. Nevertheless, the role of caveolae in
endocytosis is currently being debated. Some suggest
that caveolae are involved in transcytosis in endothelial cells
[100]. According to this hypothesis, caveolae rapidly detach
from the apical side of the membrane and fuse with the
basal one, or directly form transient pores in thin endothelial
cells [101]. Other studies have shown that in many cell
types caveolae are normally not involved in endocytosis,
but are stable invaginations present at the cell surface
[102,103], and only undergo endocytosis upon stimulation
[96,104].
Apart from these mechanisms, phagocytosis is a form of recep-
tor-mediated endocytosis of large particles (above 0.5 µm),
which requires the involvement of the cytoskeleton for mem-
brane rearrangements. Professional phagocytic cells of the
immune system use it to internalize pathogens [105]. However,
it has emerged that also non-specialized phagocytic cells can
internalize large particles [71,106].
Finally, other clathrin-independent endocytic mechanisms have
been described. These include pathways mediated by flotillins,
ADP-ribosylation factor 6, endophilins, or tubular structures
called clathrin-independent carriers (CLICs). The exact machin-
ery involved in these various clathrin-independent pathways is
still investigated and the involvement of components like actin,
cholesterol, or dynamin is often debated [71,91,92].
Overall, endocytosis is highly complex and still a very active
field of research. This is one of the factors which makes the
characterization of the mechanisms by which nano-sized mate-
rials enter cells challenging.
Beilstein J. Nanotechnol. 2020, 11, 338–353.
343
2.2 Endocytosis of nanoparticles: effects of
material properties
As we described in the Introduction, the capacity of nano-sized
objects to interact with the cellular machinery has opened up
the possibility of using nano-sized materials to deliver drugs to
their target. Nanoparticle design can be tailored to target specif-
ic cell types or pathways. Size, charge, shape [107], hydropho-
bicity [108], rigidity [109,110], roughness [111] and surface
functionalization [43,112] of nanomaterials are all parameters
that in principle can be tuned in order to affect the pathway of
internalization of nano-sized materials and ideally also to direct
them towards a specific intracellular location. Still, there is not
yet an agreement in the scientific community on the pathways
that nano-sized materials, including nanomedicines, use to enter
cells [21,22,113,114]. A better characterization of the mecha-
nisms that cells use to internalize nano-sized materials can
potentially help us to understand how to tune their design to
achieve the desired outcomes at cell level [22] (as we illustrate
in Figure 1).
Nanoparticle size: A fundamental parameter that seems to
affect the pathway of internalization of nanoparticles is their
size. A general observation is that the uptake efficiency of
nanomaterials decreases with increasing particle size [115-117],
probably because of the extensive membrane rearrangements
needed for internalization of larger objects [59,118,119]. Some
studies have compared explicitly the uptake efficiency of parti-
cles of different sizes trying to define the optimal size for
uptake [120-123]. Additionally, it is commonly believed that
most nanoparticles with sizes compatible with the size of
clathrin-coated pits enter through clathrin-mediated endo-
cytosis [115,124] and, vice versa, that larger ones do not. It
was thought that the geometry and 3D structure of clathrin
would not allow it. However, results opposing this general idea
about size have also been reported [116,125-127]. For example,
in one study using HEK293 cells, spherical polystyrene nano-
particles of 100 nm were internalized through actin-dependent
but clathrin-independent processes, and vice versa, 200 nm
nanoparticles entered by clathrin-mediated endocytosis [127].
Similarly, the uptake of 500 nm PRINT particles was reduced
by chlorpromazine (an inhibitor of clathrin-dependent endo-
cytosis) [125] and it has been shown that larger particles could
be internalized in pits coated with plaques of clathrin [128-130].
These studies, selected just as examples among many others,
already highlight the difficulties in establishing a general rule
on how nanoparticle size affects uptake. Similarly, it was
believed that particles larger than 200 nm could not be internal-
ized by non-phagocytic cells [7], while opposite observations
are often reported. For instance, even cubic nanoparticles of
3 μm could be internalized by HeLa cells [125].
Moreover, the effects of nanoparticle size on the mechanism of
uptake may be different in different cell types. For example, it
has been shown that murine RAW 264.7 macrophages have a
higher uptake efficiency for carboxylated polystyrene nanopar-
ticles compared to human endothelial HCMEC or epithelial
HeLa cells [131]. In another study using carboxylated poly-
styrene nanoparticles of different sizes in different cell types,
actin was required for the internalization of nanoparticles of
200 nm, but not for those of 40 nm in 1321N1 astrocytes.
Instead, in lung epithelial A549 cells, for both nanoparticle
sizes, the uptake was not dependent on actin [132]. Unfortu-
nately, so far, only a few studies have investigated in a system-
atic way how different cell types internalize nanoparticles of
different size, making it difficult to draw conclusions [132-
134].
Nanoparticle charge: Apart from size, charge is another easily
tunable parameter that can greatly influence the behaviour of
nanoparticles in biological media [135] and on cells [136]. In
general, positively charged nanoparticles seem to be internal-
ized more efficiently than neutral and negatively charged parti-
cles [125,137,138]. However, there are other examples showing
exactly the opposite [139]. It has also been reported that uptake
increases with charge density (either positive or negative) [140].
Regarding the pathway of internalization, some studies sug-
gested that positively charged nanomaterials are predominantly
internalized through clathrin-mediated endocytosis, with a frac-
tion of particles utilizing macropinocytosis, while negatively
charged nanoparticles are more likely to use a cholesterol-de-
pendent mechanism for their internalization [21,141]. Contra-
dicting results were reported in which clathrin-mediated endo-
cytosis did not seem to be a relevant pathway for neither posi-
tively nor negatively charged nanomaterials, while cholesterol-
mediated uptake seems to be equally important for both [142].
Similarly, another study suggested that both negatively and pos-
itively charged poly(ethylene glycol)-ᴅ,ʟ-polylactic acid parti-
cles entered, at least partially, by clathrin-mediated endocytosis
and macropinocytosis [143].
It is important to mention that many studies investigating the
effect of charge or other nanomaterial properties on cellular
interactions were performed in the absence of proteins from bi-
ological fluids such as serum. This represents a further issue
since the charge of nanomaterials tends towards neutrality upon
corona formation, once they are applied in a biological environ-
ment. Thus, nanoparticles that in water possess different
charges might end up having all a similar charge, close to neut-
rality upon exposure to biological media [135]. Because of this,
it is important to determine whether some of the described
charge-related effects disappear once the nanomaterials are
applied in a biological environment.
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Nanoparticle shape: Another tunable parameter that can influ-
ence nanoparticle–cell interactions is shape. Simulations indi-
cated that based on the energy required for membrane bending,
the uptake would be the highest for spheres followed by cubes,
then rods, and lastly discs [144]. Nevertheless, a recent in vitro
study using gold particles, showed that the number of internal-
ized particles was decreasing from rod to cubic, to spherical, to
prism-shaped nanoparticles [145]. Often the effect of shape is
studied by changing nanoparticle aspect ratio. Most of these
studies showed that the uptake is higher when the aspect ratio is
smaller [120,146,147]. This could be explained by the higher
energy required to wrap a lipid membrane around a nanoparti-
cle with high aspect ratio [148]. However, also in relation to
this aspect, conflicting results were found in which cross-linked
poly(ethylene glycol) hydrogels or mesoporous silica particles
with higher aspect ratio were internalized quicker and more
than those with low aspect ratio [125,149]. A few studies have
investigated the effect of nanoparticle shape not only on uptake
efficiency but also on the endocytic mechanisms involved in
uptake [125,134,150]. Cylindric cationic poly(ethylene glycol)
hydrogels with two different aspect ratios (1 and 3) were both
taken up by HeLa cells by a combination of clathrin-mediated
and caveolae-mediated endocytosis (based on cholesterol and
tyrosine kinase dependence) [125]. On the other hand, in
another study, the entry of cylindric, worm-like, and spherical
silica particles in A549 and RAW264.7 cells was independent
of cholesterol. Uptake of spherical silica particles was mainly
clathrin-dependent, while internalization of worm-like and
cylindric silica was primarily microtubule-dependent [134].
Similar studies on the effect of shape on the mechanism of
internalization are challenging because of different complic-
ating factors. Firstly, changing the shape also affects the dimen-
sions of the nanomaterial. This means that to compare uptake of
differently shaped objects, either the volume, maximum diame-
ter, or a combination of the dimensions should be kept constant.
Secondly, non-spherical objects can interact with the cell mem-
brane with different orientation. Thus, depending on the orien-
tation when interacting with the cell membrane, the contact area
between the nano-sized object and the cell surface differs. It is
thought that in these cases different mechanisms are then trig-
gered based on the orientation of the nanoparticles [134,150].
This might, at least in part, explain why multiple pathways
seem to be involved in the uptake of non-spherical nanomateri-
als.
Nanoparticle rigidity: Recently, there is a high interest in the
effect of the rigidity of nanoparticles on the interactions at cel-
lular level [109,110]. Simulations showed a higher energy
barrier for the internalization of soft and easily deformable
nanoparticles than for that of rigid particles [151,152]. Howev-
er, nanoparticle–cell interactions cannot be described solely by
the energy barrier required to bend the lipid membrane. Other
biological factors are also involved, possibly explaining the
contrasting results on the effect of rigidity on uptake [110,151-
154]. Indeed, while some studies found higher uptake for the
more rigid particles [151,153,155], another study suggested that
softer particles enter in higher numbers [154]. In this latter
study, it was also shown that the more rigid nanomaterial
(Young’s modulus above 13.8 MPa) was internalized by cells at
least in part via clathrin-mediated endocytosis, as opposed to
the softer material [154]. Similarly, in another study, lipid
covered PGLA particles with different Young’s modulus values
in the range of gigapascals were also partially internalized by
clathrin-mediated endocytosis [151].
Understanding how nanoparticle properties affect the
mechanism of uptake by cells: Overall, the examples
presented show that the effect of tunable nanoparticle parame-
ters such as size, charge, and shape on the mechanisms of
uptake by cells is often ambiguous. To further illustrate this
complexity, Table 1 summarizes the few preliminary observa-
tions, which we discussed in this section, including references,
which support and contrast them. We emphasize that Table 1 is
far from complete and the observations included have been
selected solely as an example to illustrate the complexity of
often contrasting outcomes reported in literature.
A reason of this ambiguity and complexity might be that
multiple mechanisms are triggered at the same time, as sug-
gested by several studies [18,115,132,156-159]. It could also be
that, besides the generally studied classical routes such as
clathrin- and caveolae-mediated endocytosis, other less well-
known pathways of internalization are involved in the uptake of
nanomedicines, such as those briefly described in Section 2.1.
Recently, computer simulations and in vitro studies of nanopar-
ticle–membrane interactions have shown that the surface of
nanomaterials can in itself induce several changes at the plasma
membrane, by determining sol–gel transitions in the lipid bilay-
er and impairing lipid lateral diffusion [160,161], or by induc-
ing bending of the plasma membrane [162,163], as already ob-
served with certain viruses [164]. These changes in membrane
dynamics might as well be a trigger for the endocytosis of nano-
particles via alternative mechanisms, which are not yet fully
characterized.
Extracting conclusions from the available literature is addition-
ally complicated by the fact that most studies have used differ-
ent conditions with respect to many factors such as, for
instance, the presence, source, and concentration of serum, but
also the nanomaterial used, the cell type, and the methods
applied to characterize the pathways involved. These differ-
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Table 1: The table summarizes few selected examples that we discuss in Section 2.2 of observations reported in literature on the effect of nanoparti-
cle properties on the mechanism of uptake by cells. References to literature with supporting as well as opposing observations are included (also dis-
cussed in Section 2.2). We emphasize that the table is far from complete and includes only a few examples, selected solely to illustrate the complexi-
ty of outcomes. In fact, we consider the observations listed still as preliminary, as also illustrated by apparently contrasting results in the opposing
studies included (in most cases performed using different conditions and systems).
reported observation or preliminary statement supporting studies opposing studies
nanoparticles uptake efficiency decreases with increasing size [107-109] [112]
nanoparticles up to 100 nm in diameter enter through clathrin-dependent
endocytosis
[107,113] [114-116]
non-phagocytic cells can only internalize materials up to 200 nm [8] [107,114]
positively charged nanoparticles are internalized more efficiently than negatively
charged or neutral nanoparticles
[114,124,125,128,130] [126,127,129]
positively charged nanoparticles enter (at least partially) through
clathrin-dependent endocytosis
[21,128,130] [129]
nano-sized objects with small aspect ratios are internalized more efficiently [112,133,134] [114,136]
more rigid nanoparticles enter more efficiently than softer nanoparticles [139,141,143] [142]
ences clearly lead to different outcomes and apparently
conflicting results. Only in a few cases, systematic studies using
a series of nanomaterials of well-defined properties have been
performed in order to try to disentangle the effect of multiple
nanomaterial properties on the cellular uptake and on other bio-
logical effects [145,165]. Unfortunately, still no clear predic-
tions can be made on how certain nanoparticle properties affect
uptake efficiency and the mechanisms involved, and more work
along these lines will be required [145,165]. Recent debates in
the nanomedicine field pushed the community to address the
issue of reproducibility and the development of standardized
procedure in nanomedicine testing and application [166,167].
Similar efforts may help to reach a better understanding of how
nanomaterial properties affect the mechanism of uptake by
cells.
3 Intracellular fate
Another important aspect to consider for nanomedicine applica-
tions is the final fate of nano-sized materials following internal-
ization. A recent review has discussed this aspect in more detail
[85]. Regardless of the route of entry, many studies report that
most nano-sized materials travel via the endosomes until
reaching their final localization in the cell, which in most cases
has been shown to be the lysosomal compartment [168,169]. In
the lysosomes, nano-sized objects, including nanomedicines,
may be degraded and release their content, if biodegradable, or
may accumulate and persist [122]. While this can be very use-
ful when the target is the lysosomes, it is well known that lyso-
somal accumulation constitutes an ulterior barrier for the
delivery of drugs to any other intracellular target [85,86]. This
has led to the development of strategies to induce escape from
the endosomal compartment, including – among others – via the
so-called “proton sponge effect” [170,171]. Materials capable to
induce this proton sponge effect started to find their application
in vivo only recently [172]. Several other strategies are being
developed, including some inspired by viruses and bacteria
capable to travel to other intracellular locations [173-176].
Several reviews fully focused on endo-lysosomal escape have
summarised current efforts in this direction [174-177].
Another open question that is debated in the field is whether
nano-sized materials, including nanomedicines, can end up in
compartments other than the lysosomes. For example, in several
reports it appears that nanoparticles can be transcytosed across
endothelial cells [178,179]. However, the existence of a dedic-
ated pathway, such as caveolae-mediated endocytosis, for tran-
scytosis of macromolecules is still debated in the endocytosis
community [96,102-104].
Understanding how cells recognize and internalize nano-sized
materials can help us to address also questions regarding the
intracellular fate of nano-sized materials and to define strategies
to direct nanomedicines towards different intracellular loca-
tions or to promote drug release in cells.
4 Challenges in studying endocytosis of
nano-sized materials in vitro
While studying the interactions between nanomaterials and cells
is extremely challenging to perform in vivo, in vitro studies can
help to unravel the mechanisms involved in their uptake. For
such studies, the nanoparticle dispersion, the cell culture condi-
tions, the cell line investigated, and the methods used to charac-
terize the uptake mechanisms are all crucial. Unfortunately,
there are often no agreements on how to perform uptake studies
in a standardized way. Recently, this problem has gotten much
attention in the nanomedicine field [166,167,180]. Within the
nanosafety community, dedicated to the study of potential
hazards of nanotechnologies, several efforts have been focused
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on the establishment of standardized procedures for nanomateri-
al handling and for cell interaction studies in order to ensure
quality in nanosafety testing [181-183]. Some of the know-
ledge gained there could be helpful also in developing similar
standards for studies aimed at characterizing how nano-sized
objects, including nanomedicines, enter cells. In the following
sections, we will describe some technical challenges concern-
ing in vitro studies of the endocytosis of nano-sized materials.
4.1 Nanoparticle dispersion in biological media:
agglomeration and corona formation
One of the most important aspects to consider when studying
nanoparticle interactions with cells, as well as when character-
izing the mechanism for their internalization, is the stability
over time and the potential agglomeration of nanoparticles in
biological media. In fact, agglomeration can strongly affect the
corona composition, the interaction with cells, as well as the
pathways of internalization [59,184,185]. Thus, it is important
to characterize the nanoparticle dispersion in the biological
media in which the nanomedicine will be applied, and to
monitor potential agglomeration and stability over time.
Additionally, studies in which nanoparticles are incubated on
cells without serum or other biological fluids may lead to
conclusions that are not relevant for biological applications and
in vivo studies, because they do not take into account corona-
related effects [186-189]. Given the impact of the corona on
both recognition and internalization of nano-sized materials, it
is important not only to include some biological fluid to allow
corona formation, but also to define the appropriate conditions
for each application [18,62-65,68,69]. For instance, there are
many in vitro studies in which nanoparticles are tested on
human cell lines using culture media containing a low percent-
age of foetal bovine serum [132,133,190-193]. Not only the
percentage of serum, but also the species from which the serum
originates, as well the use of serum heat inactivation, or the
choice of anticoagulant used to prepare plasma are some of the
factors affecting corona formation and potentially also the
subsequent mechanisms of internalization [18,62-65,68,69].
Similar considerations should be made when characterizing the
uptake of nanomedicines administered via other routes. In these
cases biological fluids other than serum should be used
[185,194].
On a more complex level, it is also known that the corona com-
position evolves over time [195-197]. Recent studies from Chan
and colleagues are trying to explore how the corona composi-
tion affects the biological interactions of nanoparticles by per-
forming mass spectrometry screenings and by developing
computational models to predict the evolution of their protein
corona [60,61,198]. Other studies are trying to understand not
only whether certain biomolecules are present on the nanoparti-
cle surface, but also their orientation, which might influence
their recognition by cell receptors [17,199]. In order to take into
account corona-related effects on nanoparticle interactions with
cells, a precise workflow to characterize the corona composi-
tion has been proposed, which might help to compare different
studies and to find a correlation between corona composition,
serum composition and, ultimately, uptake mechanisms [41].
4.2 Cell models
The cell type investigated and its tissue organization are other
important factors that can affect the uptake mechanisms of
nanoparticles. For example, not all pathways are active in all
cell types: HepG2 cells have no endogenous caveolin-1, and
therefore they are unable to internalize nanoparticles by cave-
olae-mediated endocytosis [200]. Similarly, many in vitro
studies use immortalized or cancer cell lines, such as HEK293
or HeLa cells, which are easy to transfect and culture. However,
these cells can behave quite differently in comparison to prima-
ry cells or cells isolated directly from tissues of patients. While,
on one hand, the use of primary cells can be recommended, on
the other hand, it is also a well-known obstacle for a detailed
study of cellular pathways. Most primary cells are difficult to
transfect and require interaction with other cell types for their
proper differentiation [201-203]. Another important factor
known to affect uptake pathways by cells in vitro is the differ-
entiation of cells into barriers and the resulting cell polarization
[159]. Uptake by cells grown to a polarized cell barrier is, in
fact, different than uptake by the same cells when grown isolat-
ed or simply confluent [22,159].
Apart from simpler cell cultures and cell barriers, many
advances have been made in the development of cellular models
that can better reflect the more complex organization of cells in
vivo. Models such as organoids or spheroids, which use one or
multiple cell lines organized into 3D structures, have been de-
veloped and are likely to become useful also for nanomedicine
uptake studies.
4.3 Methods to characterize uptake mechanisms
Further difficulties in the study of the uptake mechanisms of
nano-sized materials, such as nanomedicines, arise from the fact
that endocytosis represents a complex cellular process with
many molecules, feedback loops, and signalling cascades
involved. The endocytosis field is still very active and constant-
ly progressing [71,77,204]. Many processes and molecular
details of these pathways are still unknown. For instance, in
recent years much attention has been paid to non-canonical
pathways of endocytosis [71,91,92], which are often more diffi-
cult to study, but which might as well constitute possible routes
for the internalization of nano-sized materials. In light of this
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complexity, the tendency within the nanomedicine field to clas-
sify the pathways of internalization of drug carriers as merely
macropinocytosis, clathrin-dependent, or caveolae-dependent is
for sure an oversimplification. Furthermore, the classification
and description of the different mechanisms of uptake by cells
are often revised and corrected in the endocytosis field, as
research progresses. This is an example of the challenges that
interdisciplinary fields such as nanomedicine need to face. In
this context, a closer connection with the cell biology and endo-
cytosis communities is desirable [113].
Typical experiments to characterize uptake mechanisms are
carried out by altering cellular pathways using different
methods in order to determine their involvement in nanoparti-
cle uptake. However, it is well established that perturbation of a
cellular mechanism might as well lead to the alteration of other
mechanisms. Therefore, when performing such studies, it is im-
portant to have appropriate controls to verify the effect of the
selected treatment on the pathway of interest and exclude poten-
tial artefacts of this kind [22,133,158].
The selection of appropriate controls poses further challenges.
For example, fluorescently labelled low-density lipoprotein and
transferrin can be used as markers for clathrin-mediated endo-
cytosis [205,206], dextran as a fluid phase marker for phagocyt-
osis and for the CLEE/GEEC pathway [193], and LacCer (C5-
lactosylceramide) for cholesterol-dependent uptake [133,207].
However, while cholera toxin and SV40 were previously used
as markers of caveolae-mediated endocytosis [95], they have
been found to enter cells using preferentially other routes and
thus should not be used anymore as markers for this pathway
[208-210]. Furthermore, selecting an appropriate control marker
can be challenging for several of the more recently described
clathrin- and caveolae- independent pathways.
Next to the difficulties related to the choice of control markers,
the fact that the endocytic pathways are strongly interconnected
and that some components take part in multiple mechanisms
also complicates further the interpretation of results. As an ex-
ample of this, cytochalasin D, an inhibitor of actin polymeriza-
tion [211], has often been used to test the involvement of
macropinocytosis and phagocytosis in the uptake of nanomate-
rials. However, actin has been shown to be important also for
other mechanisms, including clathrin-mediated endocytosis and
caveolae-mediated endocytosis. Hence, perturbing the activity
of actin affects multiple pathways at the same time [212].
Several techniques can be used for studying the endocytic
mechanisms of nano-sized materials, each one with its advant-
ages and drawbacks [22,133]. Among those, RNA interference
(RNAi) is often used to shut down the expression of a single
protein or even a single isoform. However, the complete deple-
tion of the protein of interest after RNAi requires at least
48–96 h and during this time cells can adapt, for example by
upregulating other proteins of the same family or other
pathways. Moreover, RNAi does not guarantee the total deple-
tion of a protein from the cell, and in some cases the partial
reduction of a protein is not sufficient to fully inhibit its func-
tion [22].
Apart from RNAi, so far, many studies on the uptake of nano-
sized materials make use of transport inhibitors, whose action
on cells is instead very fast. However, some of these inhibitors
lack specificity, they might interfere with multiple pathways,
and they can cause cellular toxicity [22,133,158,213]. In
contrast to these approaches to block uptake pathways, other
strategies can be found in which proteins are instead overex-
pressed, in order to eventually detect an increase in nanoparti-
cle uptake [17]. Nevertheless, also these methods might lead to
artefacts, since the overexpression might induce the activation
of a pathway that may not be active under physiological condi-
tions [22,214]. Furthermore, some proteins act as heterodimers
or in concert with other molecular partners, thus their overex-
pression might not produce any detectable effect if not
combined with the overexpression of those partners as well.
Overexpression is often used to allow for the visualization of
fluorescently tagged molecules by microscopy. However, also
this might lead to additional artefacts. For example, it has been
shown that overexpression of GFP-tagged caveolin 1 (CAV1-
GFP), the main constituent of caveolae-mediated endocytosis,
leads to the creation of artefacts, such as the observation of a
specialized endosomal compartment for caveolae, the “caveo-
some” [214].
Recent advances in cellular imaging and gene editing could
overcome some of these issues. For instance, the use of stably
transfected cell lines might be a good solution when the total
depletion of a protein is required to shut down a pathway (often
difficult to achieve with techniques such as RNAi), but also for
expressing labelled proteins at physiological levels, thereby
avoiding the aforementioned artefacts connected to overexpres-
sion. The creation of specific transgenic cell lines to study
nanoparticle uptake has been greatly enhanced by gene editing
techniques such as CRISPR/CAS9, which allows to cut genes in
a much more specific and efficient way than with previously
existing methods [215,216]. Similar methodologies can
improve our understanding of the involvement of specific pro-
teins in the internalization of nanoparticles.
Other recently developed techniques that are available in
cell biology to characterize pathways and that have not yet
been used to study the uptake of nano-sized materials
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may provide novel insights into this difficult question. For
instance, so-called OMICS approaches based on large-scale
proteomics and full genome screenings could be of particular
use [217-219]. While most of the “classical” methods
mentioned so far require previous knowledge on the mecha-
nisms of uptake by cells, a reverse approach could allow for
discovering novel targets not yet associated with the endo-
cytosis of nanomaterials.
Overall, it is clear that none of these different methods, alone,
can provide a full picture of the mechanisms that nano-sized
materials use to interact with cells since they all display differ-
ent advantages and pitfalls [22,133,158]. The combination of
different techniques and the application of proper controls could
help us to gain a better knowledge of the endocytic processes
involved in the uptake of nano-sized materials.
Conclusion
Nanomedicine aims at delivering drugs more efficiently to their
target to treat diseases. Designing the properties of nano-sized
materials to be able to control the interactions and the behav-
iour at cell level is one of the key steps required for successful
targeting. Nanomedicines can be functionalized by the addition
of targeting moieties to be recognized by specific receptors on
the targeted cells. However, achieving this initial recognition
for active targeting still holds many challenges.
Additionally, it has emerged that when nano-sized materials are
applied in a biological environment, corona formation affects
the initial recognition by cells, as well as the following mecha-
nisms of internalization. However, many aspects of the initial
recognition of nano-sized materials by cell receptors still need
to be understood. Similarly, how the initial recognition affects
the following mechanisms of internalization remains to be elu-
cidated and an agreement in the scientific community about the
pathways that nano-sized materials, such as nanomedicines, use
to enter cells is still missing.
Several factors complicate these studies and make it difficult to
draw clear conclusions. The field of endocytosis is still very
active and novel pathways are still being described. At the same
time there are limits and challenges regarding the many differ-
ent methods available to characterize uptake mechanisms and
the lack of standardized procedures makes it difficult to draw
conclusions from available studies. Using a combination of
methods and appropriate controls to study the mechanisms by
which cells internalize nano-sized materials could potentially
help us to understand how these are affected by nanomaterial
properties. In this way, nanomedicine design could be tuned to
achieve the desired outcomes at cell level and engineer nanoma-
terials for more efficient drug targeting.
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